Thanks, Paul. Good afternoon, everyone, and welcome to the Kingsway earnings call for the second quarter of 2024. We had a solid quarter that was largely in line with our expectations. We saw improving performance in our Extended Warranty segment, which showed strong cash sales and moderating claims experience and we exited the quarter with nice momentum heading into the back half of the year. Our KSX segment also performed well with EBITDA improving sequentially and year-over-year. Additionally, this quarter has been marked by very positive deal-related activity. We have a couple of promising high-quality prospects that we are working on, which, if completed, would significantly contribute to our growth trajectory moving forward. For the second quarter of 2024, consolidated revenue was $26.4 million, a modest increase of 1% compared to the prior year quarter, while consolidated adjusted EBITDA was $2.4 million, a nice improvement over the $1.8 million in the year ago quarter. For the Extended Warranty segment and the KSX segment, combined adjusted EBITDA was $3.4 million in both the second quarter of this year and last year. In our Extended Warranty segment, the pricing adjustments that were implemented beginning in the second half of 2023 are having a positive impact in helping to offset claims expense, which increased only 2.9% over the prior year. You may recall that Q1 claims were 13.1% higher than last year. Also notably, our cash sales for the current quarter increased 4.6% over the prior year. Sequentially, adjusted EBITDA increased 12% from the first quarter of 2024, driven by higher earned revenue, a higher mix of Extended Warranty revenue at Trinity and our ongoing focus on controlling costs. As we talked about during our last earnings call, the challenges faced by the businesses in Extended Warranty have moderated, and we feel that we hit an inflection point in the second quarter. Turning to our Kingsway Search Xcelerator, or KSX segment. Revenues increased 2% over prior year, primarily due to a favorable comparison resulting from the acquisitions of SPI and DDI in the second half of 2023. Ravix continues to perform both ahead of our original investment thesis and is trending nicely in 2024. The team at Ravix remains focused on increasing utilization rates, optimizing pricing and disciplined cost management. While revenues were down in the quarter, gross margins continue to hold around 37%, a 200 basis point improvement over prior year. EBITDA was essentially flat year-over-year in the quarter. At CSuite, the team is building a solid pipeline, and we continue to believe the business is headed in the right direction despite persistently challenging market conditions. Revenue and adjusted EBITDA were lower in the second quarter compared to the prior year period. However, cost of sales and general and administrative expenses were also down from prior year. The pipeline of qualified new business opportunities look strong and the team is charting its course for accelerating revenue in the second half of 2024 and beyond. At SNS for the second quarter, revenue was flat sequentially, but both gross margin and adjusted EBITDA improved due to a higher mix of travel nurse shifts in the current quarter. Gross margin was over 200 basis points better in Q2 than in Q1. Travel shifts increased 35.4% from the first quarter and the number of nurses on travel assignment or TOA, has more than doubled since the beginning of the year. For the first time in a long while, the company exits the quarter with more TOA than at the same point last year. We continue to believe the longer-term outlook for the travel nurse market is promising. At Systems Product International, or SPI, the team delivered strong revenue and adjusted EBITDA in Q2 with revenues increasing 24% sequentially. The company has contracted with a number of new clients this year and is executing on its strategy to grow annual recurring revenue. Since acquisition, the company has grown ARR by 12%. At Digital Diagnostics Imaging or DDI, revenue continues to be strong, increasing 14.6% over the prior year. EBITDA improved by 26.2% over the prior year period. To support its growth strategy and diversify its operational risk, DDI recently signed a new lease for a second operation center in Salt Lake City. We expect to have the location up and running in the second half of the year. The company continues to meet and exceed our original expectations. Based on the performance of our operating businesses, the 12-month run rate adjusted EBITDA remains at $16 million to $17 million. As a reminder, run rate is intended to capture the last 12 months of adjusted EBITDA for the businesses we currently own, including those we have recently acquired. Growth through acquisitions remains central to our corporate strategy, targeting opportunities that deliver predictably high returns on tangible capital in large and growing end markets. While the timing of completing transactions is challenging to predict, we are seeing a healthy level of activity related to potential transactions and believe we are on track to meet our target of 2 to 3 deals each year that can each generate $1 million to $3 million in annualized adjusted EBITDA. We currently have 4 highly talented operators in residence or OIR, who are actively searching for opportunities and are currently evaluating a number of attractive potential acquisition targets. In addition, we are actively recruiting new OIRs that can backfill and grow our bench of talent as our deal flow evolves. All in all, strong execution in the Extended Warranty businesses and continued progress against strategic objectives within our KSX businesses drove solid financial results for the second quarter. I'll now turn the call over to Kent for some additional commentary related to our financials.